249 related articles for article (PubMed ID: 23812226)
1. Bolus 5-fluorouracil as an alternative in patients with cardiotoxicity associated with infusion 5-fluorouracil and capecitabine: a case series.
Saif MW; Garcon MC; Rodriguez G; Rodriguez T
In Vivo; 2013; 27(4):531-4. PubMed ID: 23812226
[TBL] [Abstract][Full Text] [Related]
2. Bolus 5-Fluorouracil as an alternative modality to infusion 5-Fluorouracil in a patient with rectal cancer and capecitabine-induced cardiotoxicity.
Shaib W; Lee V; Saif MW
In Vivo; 2009; 23(5):821-6. PubMed ID: 19779118
[TBL] [Abstract][Full Text] [Related]
3. Alternative treatment options in colorectal cancer patients with 5-fluorouracil- or capecitabine-induced cardiotoxicity.
Deboever G; Hiltrop N; Cool M; Lambrecht G
Clin Colorectal Cancer; 2013 Mar; 12(1):8-14. PubMed ID: 23102544
[TBL] [Abstract][Full Text] [Related]
4. Cardiotoxicity of 5-fluorouracil and capecitabine in a pancreatic cancer patient with a novel mutation in the dihydropyrimidine dehydrogenase gene.
Shahrokni A; Rajebi MR; Harold L; Saif MW
JOP; 2009 Mar; 10(2):215-20. PubMed ID: 19287123
[TBL] [Abstract][Full Text] [Related]
5. [Cardiotoxicity induced by 5-fluorouracil or capecitabine].
Jensen SA; Baeksgaard L; Petersen LN; Reiter L; Sørensen JB
Ugeskr Laeger; 2010 Jan; 172(1):48-51. PubMed ID: 20056096
[TBL] [Abstract][Full Text] [Related]
6. Use of raltitrexed as an alternative to 5-fluorouracil and capecitabine in cancer patients with cardiac history.
Kelly C; Bhuva N; Harrison M; Buckley A; Saunders M
Eur J Cancer; 2013 Jul; 49(10):2303-10. PubMed ID: 23583220
[TBL] [Abstract][Full Text] [Related]
7. Dihydropyrimidine dehydrogenase gene (DPYD) polymorphism among Caucasian and non-Caucasian patients with 5-FU- and capecitabine-related toxicity using full sequencing of DPYD.
Saif MW
Cancer Genomics Proteomics; 2013; 10(2):89-92. PubMed ID: 23603345
[TBL] [Abstract][Full Text] [Related]
8. Risk factors and prevention of cardiotoxicity induced by 5-fluorouracil or capecitabine.
Jensen SA; Sørensen JB
Cancer Chemother Pharmacol; 2006 Oct; 58(4):487-93. PubMed ID: 16418875
[TBL] [Abstract][Full Text] [Related]
9. Cardiotoxicity of fluoropyrimidines in different schedules of administration: a prospective study.
Kosmas C; Kallistratos MS; Kopterides P; Syrios J; Skopelitis H; Mylonakis N; Karabelis A; Tsavaris N
J Cancer Res Clin Oncol; 2008 Jan; 134(1):75-82. PubMed ID: 17636329
[TBL] [Abstract][Full Text] [Related]
10. Capecitabine cardiotoxicity--case reports and literature review.
Manojlovic N; Babic D; Stojanovic S; Filipovic I; Radoje D
Hepatogastroenterology; 2008; 55(85):1249-56. PubMed ID: 18795667
[TBL] [Abstract][Full Text] [Related]
11. Capecitabine plus oxaliplatin for the treatment of colorectal cancer.
Carrato A; Gallego-Plazas J; Guillén-Ponce C
Expert Rev Anticancer Ther; 2008 Feb; 8(2):161-74. PubMed ID: 18279056
[TBL] [Abstract][Full Text] [Related]
12. Capecitabine: a review.
Walko CM; Lindley C
Clin Ther; 2005 Jan; 27(1):23-44. PubMed ID: 15763604
[TBL] [Abstract][Full Text] [Related]
13. Severe sequence-specific toxicity when capecitabine is given after Fluorouracil and leucovorin.
Hennig IM; Naik JD; Brown S; Szubert A; Anthoney DA; Jackson DP; Melcher AM; Crawford SM; Bradley C; Brown JM; Seymour MT
J Clin Oncol; 2008 Jul; 26(20):3411-7. PubMed ID: 18612156
[TBL] [Abstract][Full Text] [Related]
14. A case of capecitabine-induced coronary microspasm in a patient with rectal cancer.
Arbea L; Coma-Canella I; Martinez-Monge R; García-Foncillas J
World J Gastroenterol; 2007 Apr; 13(14):2135-7. PubMed ID: 17465463
[TBL] [Abstract][Full Text] [Related]
15. Preoperative chemoradiotherapy for rectal cancer: a comparison between intravenous 5-fluorouracil and oral capecitabine.
Ramani VS; Sun Myint A; Montazeri A; Wong H
Colorectal Dis; 2010 Aug; 12 Suppl 2():37-46. PubMed ID: 20618366
[TBL] [Abstract][Full Text] [Related]
16. Costs associated with complications are lower with capecitabine than with 5-fluorouracil in patients with colorectal cancer.
Chu E; Schulman KL; Zelt S; Song X
Cancer; 2009 Apr; 115(7):1412-23. PubMed ID: 19195048
[TBL] [Abstract][Full Text] [Related]
17. Preoperative chemoradiotherapy with capecitabine versus protracted infusion 5-fluorouracil for rectal cancer: a matched-pair analysis.
Das P; Lin EH; Bhatia S; Skibber JM; Rodriguez-Bigas MA; Feig BW; Chang GJ; Hoff PM; Eng C; Wolff RA; Delclos ME; Krishnan S; Janjan NA; Crane CH
Int J Radiat Oncol Biol Phys; 2006 Dec; 66(5):1378-83. PubMed ID: 17056196
[TBL] [Abstract][Full Text] [Related]
18. Patients with locally advanced and metastatic colorectal cancer treated with capecitabine versus 5-fluorouracil as monotherapy or combination therapy with oxaliplatin: a cost comparison.
Chu E; Schulman KL; McKenna EF; Cartwright T
Clin Colorectal Cancer; 2010 Oct; 9(4):229-37. PubMed ID: 20920995
[TBL] [Abstract][Full Text] [Related]
19. Capecitabine induced cardiotoxicity: a case report and review of literature.
Tunio MA; Hashmi A; Shoaib M
Pak J Pharm Sci; 2012 Jan; 25(1):277-81. PubMed ID: 22186341
[TBL] [Abstract][Full Text] [Related]
20. Capecitabine plus oxaliplatin for the first-line treatment of elderly patients with metastatic colorectal carcinoma: final results of the Southern Italy Cooperative Oncology Group Trial 0108.
Comella P; Natale D; Farris A; Gambardella A; Maiorino L; Massidda B; Casaretti R; Tafuto S; Lorusso V; Leo S; Cannone M
Cancer; 2005 Jul; 104(2):282-9. PubMed ID: 15948167
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
